Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OREXIGEN THERAPEUTICS INC. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
OREXIGEN THERAPEUTICS INC
OREXIGEN THERAPEUTICS INC
Contrave market share stabilizing
18 Nov 16
The third quarter was one of transition for both Orexigen and the Contrave franchise as Takeda stopped detailing the obesity drug in the United States and Orexigen took up the mantle. Contrave market share fell from 7% to 6% in wake of the announcement, but prescription data indicate it is stabilizing. Outside of the US, progress continues as the product has launched in South Korea and five countries in Central and Eastern Europe (CEE) with launches in another six CEE countries expected in Q416.
In control of its own destiny
19 Aug 16
Orexigen has completed the reacquisition of the US rights to Contrave from Takeda, putting it in control of its own destiny as it is no longer depending on a partner. However, with this opportunity comes quite a bit of risk as operating expenses will balloon to $200m per year over the next few years, more than double the previous level thanks to the need to hire an internal salesforce of 160. These increased expenses are the main reason we are lowering our valuation from $14.70 to $4.80 per share.
Taking control of Contrave
12 Apr 16
On 15 March Orexigen announced the acquisition of US distribution rights to its obesity treatment Contrave from Takeda. The company simultaneously announced a new collaboration with Valeant for the commercialization of Mysimba (Contrave ex-US) in 18 Central and Eastern European countries. We value Orexigen at $213m, significantly reduced from $1.09bn, mainly on reduced expectations for Contrave in the US. However, our fair value of $1.47/share is substantially above the current $0.51 share price.
Contrave - leading branded weight loss medicine
14 Dec 15
There is reason to be optimistic about Contrave after its progress vs competitors following launch just over one year ago and the backing of a dedicated salesforce of 900, through partner Takeda, selling into a massive potential market. Contrave was approved in the EU in March and recently signed a commercialization agreement with Kwang Dong in South Korea, communicating its ex-US strategy in its Q3 conference call whereby it plans a territory-by-territory approach. On our analysis, the strong pull back in the stock in recent months, due in part to disappointing interim results of the subsequently withdrawn LIGHT study, provides investors with an attractive entry. We value Orexigen at $1.09bn or $7.49 per share.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.